4th Anglo-Swedish Medicinal Chemistry Symposium
15th-18th March 2009, Lund, Sweden
Introduction
This conference is the 4th symposium organized jointly between the Medicinal Chemistry Section of the Swedish Academy of Pharmaceutical Sciences and the Biological and Medicinal Chemistry Sector of the Royal Society of Chemistry. The aim of the symposium is to promote the very best of medicinal chemistry in a stimulating environment. The previous meetings have been held biennially since 2003, each with over 100 delegates from all over the world.

Programme Outline
The programme consists of five sessions. Many of the medicinal chemistry talks will be “first disclosures” whilst the ‘enabling sessions’ on ‘achieving tissue selectivity’ and ‘new trends in drug discovery’ will be presented by experts from across the industry. The symposium is also designed to provide plenty of opportunities to meet other delegates, renew friendships and foster new contacts.

Poster Session
Participants are encouraged to present a poster in English and will get a 500 SEK discount on the delegate fee. Please indicate on the booking form if you intend to do a poster presentation. Poster abstracts (single A4 page, heading in Arial font 14pt and all other texts in Times New Roman 12pt) should be sent electronically to Dr. Göran Lidgren goran.lidgren@swepharm.se by 6th February 2009.

Venue & Language
The meeting will take place in Lund, a beautiful university town in the south of Sweden. The Symposium will start with registration and a welcome reception at Scandic Hotel on Sunday evening, March 15th and will finish around 1 pm on Wednesday, March 18th. The scientific sessions will be held in the Lecture Theatre at AstraZeneca R&D in Lund. The symposium language is English.

How to get there?
Lund is easily accessible (ca 40 minutes) by direct trains from Copenhagen Airport or by bus from Malmö Airport.

Sponsor Opportunities and Company Exhibition
The Organizing Committee is pleased to offer sponsorship opportunities to organizations and companies. Sponsors will be recognized in the abstract book and at the opening and closing ceremonies of the conference. In connection with the meeting there will also be an Exhibition with the opportunity to have a company booth or stand. Price level is 6000 SEK (VAT excl.) for a ca. 2x2 m² space.

Participation Fee and Accommodation
The participation fee is SEK 4400* for academic researchers and SEK 5800* for industry delegates if registration is received before January 18th 2009. From that date the fee is SEK 5900* for academic researchers and SEK 7300* for industry delegates. Poster presenters receive a 500 SEK reduction off the fee.

* VAT excl.
The fee includes documentation, welcome reception, meals and coffee (including symposium dinner) according to the programme. Accommodation is not included in the participation fee, but sufficient rooms have been reserved at the Scandic Star Hotel in Lund at a discounted rate of 1400 SEK/night (excl. VAT). Early registration is strongly recommended due to limited number of places!

Cancellations, Substitutions
The participation fee will be reimbursed in full if written cancellation is received before February 10th, 2009. Cancellations received after this date are not reimbursable. The cost for booked accommodation follows the cancellation rules of the Hotel. A substitute participant is of course welcome to attend, but please always inform the responsible Symposium Secretary.

Further Information
If you have any questions about this meeting, please contact Symposium Secretary Diana Mickels. Phone +46 (0) 8-7235085, diana.mickels@lakemedelsakademin.se

Registration can be made online at www.lakemedelsakademin.se or by post using the attached form.
PROGRAMME

Sunday 15th March

18:00-19:00 Registration
19:00-21:00 Welcome Reception at Hotel Scandic Star

Monday 16th March

Morning Session, 08:30-12:00: Kinases and ATPases
Chairman: Carlos Garcia-Echeverria, Novartis Institutes for Biomedical Research, Switzerland
Structure based design of Eg5 inhibitors for cancer treatment
Paul Barsanti, Novartis Institutes for Biomedical Research
Mining of kinase conformational switching pockets. Application to drug discovery and development
Daniel L Flynn, Deciphera
Identification and optimization of selective small molecular inhibitors of mTOR kinase
Kurt G Pike, AstraZeneca
Balancing Selectivity and Developability – Optimisation of a Novel Series of p38 Inhibitors
Stephen Swanson, GSK
13:00-16:00 Poster Session

Evening Session, 17:00-19:00: Overcoming Problems with Multi-Functional Targets - Achieving Selectivity by Tissue Distribution
Chairman: Alexander Humphries, AstraZeneca, UK
Discovery of a Rationally Designed Orally Efficacious HMG Co-A Reductase Inhibitor with Reduced Myotoxicity Potential
Saleem Ahmad, Bristol Myers Squibb
Brain penetrant alpha 1A partial agonists for the treatment of stress urinary incontinence
Lee Roberts, Pfizer
Inhaled Adenosine A2a agonists for the treatment of COPD
Simon Mantell, Pfizer
19:30 Dinner

Tuesday 17th March

Morning Session, 08:30-12:00: Enzymes and Transporters
Chairman: Austen Pimm, AstraZeneca, UK
Charles Hedgerock, CHAB, Sweden
The discovery of AZD2281, a novel, bioavailable inhibitor of Poly (ADP-ribose) Polymerase-1
David Rudge, AstraZeneca Kudos
Discovery of Lu AA21004: A novel compound for the treatment of mood disorders
Benny Bang-Andersen, Lundbeck
Discovery of potent and selective GlyT1 inhibitors for Schizophrenia
Emmanuel Pinard, F. Hoffmann La Roche.
13:00-17:00 Excursion Tour

Evening Session, 17:00-19:00: Challenges and new trends in Medicinal Chemistry
Chairman: Thomas Elebring, AstraZeneca R&D Mölndal, Sweden
Medicinal Chemistry Strategies to Overcome Attrition
Paul Leeson, AstraZeneca
Inhalation by Design
Mark Bunnage, Pfizer
The use of metabonomics in drug discovery
Ian Wilson, AstraZeneca
19:30 Conference Dinner

Wednesday 18th March

Morning Session, 08:30-12:00: GPCRs
Chairman: Adrian Hall, GSK
CCR5 antagonists for the treatment of HIV- The discovery and optimization of an Imidazopiperidine Series
Paul Stupple, Pfizer
5-HT6 Receptor Antagonists for the Symptomatic Treatment of AD: From Discovery to Clinic
Mahmood Ahmed, GSK, Singapore
The Discovery of g-Carbolines as Peripherally-Restricted CB1 Agonists for the Treatment of Pain - Hit Generation and Hit to Lead
Mirek Tomaszewski, AstraZeneca
Closing Words
Dave Alker
12:15-13:15 Lunch

For continuously updated programme see www.lakemedelsakademin.se
### Booking Form

**4th Anglo-Swedish Medicinal Chemistry Symposium, March 15th–18th, 2009**

Please register me for the 4th Anglo Swedish Medicinal Chemistry Symposium

- [ ] I am an industry delegate
- [ ] I am an academic researcher
- [ ] I wish to present a poster
- [ ] I want accommodation at discount rate at Scandic Hotel Lund

**Poster Title:**

Name: ___________________________  Date of Birth (ymmd): ___________________________

Company incl. building: ___________________________  Department: ___________________________

Company Address: ___________________________

Post Code: ___________________________  City: ___________________________

Invoice Address if not the above: ___________________________

Phone: ___________________________  Mobile: ___________________________  Fax: ___________________________

E-mail: ___________________________

Please indicate any special requirements (e.g. Dietary):

<table>
<thead>
<tr>
<th>Date</th>
<th>Signature</th>
</tr>
</thead>
</table>

Fax: +46-(0)8-20 55 11

Mail: Läkemedelsakademin, att: Diana Mickels, P.O. Box 1136, SE-111 81 Stockholm, Sweden.

www.lakemedelsakademin.se